Posted on February 7, 2020 by Sitemaster
So your sitemaster has been looking through the full report from the APCCC meeting held in Basel last year — as he promised he would. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: advanced, castration-resistant, consensus, hormone-naive, hormone-sensitive, mCRPC, metastatic, mHSPC, nmCRPC, nmHSPC, non-metastatic | 2 Comments »
Posted on December 25, 2015 by Sitemaster
Back in May 2015, James et al. reported on the survival benefits associated with androgen deprivation therapy (ADT) + docetaxel-based chemotherapy compared to ADT alone as first-line therapy for treatment-naive men initially diagnosed with metastatic prostate cancer. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: ADT, chemotherapy, docetaxel, hormone-naive, metastatic, STAMPEDE | 4 Comments »
Posted on April 10, 2015 by Sitemaster
A currently unanswered question being addressed in clinical trials is whether the oral agent enzalutamide (Xtandi) is effective and safe as monotherapy in the treatment of progressive, hormone-naive prostate cancer (i.e., before the use of other drugs such as the LHRH agonists and other forms of androgen deprivation therapy [ADT]). … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: enzalutamide, hormone-naive, monotherapy | 2 Comments »
